Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 8/20 | 0.51 |
| ▸ | CDK2 | P24941 | 7/20 | 0.51 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13289093 | 0.94 | CDK2 (0.48) | GSK3BCDK2CCNA2CCNA1NR1I2 | |
| SCHEMBL13288909 | 0.94 | CDK2 (0.50) | GSK3BCDK2CCNA2CCNA1NR1I2 | |
| SCHEMBL13289444 | 0.90 | CDK2 (0.49) | GSK3BCDK2CCNA2CCNA1RET | |
| SCHEMBL13120776 | 0.90 | CDK2 (0.65) | GSK3BCDK2CCNA2CCNA1 | |
| SCHEMBL13289016 | 0.90 | CDK2 (0.46) | GSK3BCDK2CCNA2CCNA1RET | |
| SCHEMBL13289121 | 0.90 | CDK2 (0.46) | GSK3BCDK2CCNA2CCNA1RET | |
| SCHEMBL13288974 | 0.90 | CDK2 (0.52) | GSK3BCDK2CCNA2CCNA1MEN1 | |
| SCHEMBL13288905 | 0.90 | CDK2 (0.51) | GSK3BCDK2CCNA2CCNA1RET | |
| SCHEMBL13288956 | 0.89 | CDK2 (0.48) | GSK3BCDK2CCNA2CCNA1RET | |
| SCHEMBL13288985 | 0.89 | CDK2 (0.48) | GSK3BCDK2CCNA2CCNA1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2194058-A1 | Pyrazolopyrimidines suitable for the treatment of cancer diseases | SCHERING CORPORATION (US) | 2010-06-09 | — | — | EP | disclosed |